Accepted for Publication: April 13, 2012.
Published Online: July 16, 2012. doi:10.1001/archneurol.2012.1282
Author Contributions: Drs Doecke and Laws contributed equally to this manuscript. Study concept and design: Doecke, Wilson, Bush, Ellis, Head, Ames, Masters, and Martins. Acquisition of data: Laws, Brown, De Ruyck, Ellis, Fowler, Pertile, Rowe, Rembach, Rodrigues, Rumble, Szoeke, K. Taddei, T. Taddei, and Trounson. Analysis and interpretation of data: Doecke, Laws, Faux, Wilson, Burnham, Lam, Mondal, Bedo, Gupta, and Macaulay. Drafting of the manuscript: Doecke, Laws, Faux, Wilson, Mondal, Macaulay, Pertile, Rodrigues, Rumble, and Ames. Critical revision of the manuscript for important intellectual content: Doecke, Faux, Wilson, Burnham, Lam, Bedo, Bush, Brown, De Ruyck, Ellis, Fowler, Gupta, Head, Macaulay, Rowe, Rembach, Szoeke, K. Taddei, T. Taddei, Trounson, Ames, Masters, and Martins. Statistical analysis: Doecke, Laws, Faux, Wilson, Burnham, Mondal, and Bedo. Obtained funding: Bush, Head, Macaulay, Rowe, Szoeke, Ames, and Martins. Administrative, technical, and material support: Wilson, Bush, Brown, De Ruyck, Ellis, Fowler, Gupta, Macaulay, Pertile, Rembach, Rumble, Szoeke, K. Taddei, T. Taddei, Trounson, and Masters. Study supervision: Laws, Wilson, Ellis, Macaulay, Szoeke, Ames, and Martins. Data mining: Lam.
Funding/Support: Data collection and sharing for this project was funded by the ADNI (National Institutes of Health [NIH] grant U01 AG024904). The ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Abbott Laboratories; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Amorfix Life Sciences Ltd; AstraZeneca; Bayer HealthCare; BioClinica, Inc; Biogen Idec Inc; Bristol-Myers Squibb Company; Eisai Inc; Elan Pharmaceuticals Inc; Eli Lilly and Company; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc; GE Healthcare; Innogenetics, NV; Janssen Alzheimer Immunotherapy Research & Development, LLC; Johnson & Johnson Pharmaceutical Research & Development LLC; Medpace, Inc; Merck & Co, Inc; Meso Scale Diagnostics, LLC; Novartis Pharmaceuticals Corporation; Pfizer Inc; Servier; Synarc Inc; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research provides funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the NIH (http:// www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. The ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of California, Los Angeles. This research was also supported by NIH grants P30 AG010129 and K01 AG030514. Core funding for the study was provided by CSIRO and the Science and Industry Endowment Fund (SIEF) (http://www.SIEF.org.au), which was supplemented by in-kind contributions from the study partners (see http://www.aibl.csiro.au/). The AIBL investigators thank Dr Head of CSIRO for initiating and facilitating the AIBL collaboration. The study also received support from the National Health and Medical Research Council (NHMRC) via the Dementia Collaborative Research Centres program (DCRC2). Pfizer International, AstraZeneca, and GE Healthcare have contributed financial support to further the AIBL research program. The McCusker Foundation has contributed financial and in-kind support to AIBL. Dr Faux is supported by an NHMRC training fellowship. Drs Laws and Gupta were supported through the Office of Research and Innovation at Edith Cowan University. Dr Szoeke is partially supported by a research fellowship funded by Alzheimer's Australia. Alzheimer's Australia (Victoria and Western Australia) assisted with promotion of the study and the screening of telephone calls from volunteers.
Additional Information: Data used in preparation of this article were obtained from the ADNI database (http://www.adni.loni.ucla.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report.
Additional Contributions: We thank all those who participated in the study for their commitment and dedication to helping advance research into the early detection and causation of AD.